Appendix 4C and Quarterly Activities Report - March 2026
Filed with ASX · · 8 pages · English
Summary by 6ix AI
The report highlights progress in its oesophageal cancer program, advancements in animal health collaborations, and the expansion of its skin cancer trial. Additionally, Invion secured commitments from a convertible note offering, which is expected to support ongoing clinical trials and operational costs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Invion
- Skin Cancer Trial Moves to BCC With More Encouraging Signals
- Appendix 4D and Half Year Financial Report
- Appendix 4C and Quarterly Activities Report - December 2025
- Major Shareholders Lead Invion $1.3M Capital Raise
- Trading Halt
Later from Invion
- Photosoft Platform Expands to Eye Diseases Via Partnership
- Appendix 4C and Quarterly Activities Report - June 2026
- Recruitment Conclusion for Ph 1 NMSC Trial & Advance to Ph 2
- Funding Agreements Cover Up to 85% of Clinical Trials Costs
- Appendix 4C and Quarterly Activities Report - September 2026
Follow Invion into a list and get an email when it puts out news.
Follow Invion